Global News Distribution

health

Progesterone Market is Projected to Experience Promising Growth Opportunities in the Coming Years

November 3, 2021 (Global News Distribution) -

Progesterone is the naturally occurring steroid hormone that is produced in adrenal glands, ovary, and placenta (during pregnancy). Progesterone is mainly involved in the maintenance of pregnancy, regulation of menstrual cycle, and embryogenesis. Low progesterone levels may lead to constant breast tenderness, abdominal pain, fatigue, and even miscarriage or fetal death. During this phase, progesterone is given to the patient to prevent the aforementioned conditions.

Progesterone Market Report provides an overview of the market based on key parameters such as market size, sales, sales analysis and key drivers. The market size of the market is expected to grow on a large scale during the forecast period (2021-2030). This report covers the impact of the latest COVID-19 on the market. The coronavirus epidemic (COVID-19) has affected all aspects of life around the world. This has changed some of the market situation. The main purpose of the research report is to provide users with a broad view of the market. Initial and future assessments of rapidly.

Explore Report Description@ https://www.alliedmarketresearch.com/progesterone-market

The Covid-19 (corona virus) pandemic is impacting society and the overall economy across the world. The impact of this pandemic is growing day by day as well as affecting the supply chain. The COVID-19 crisis is creating uncertainty in the stock market, massive slowing of supply chain, falling business confidence, and increasing panic among the customer segments. The overall effect of the pandemic is impacting the production process of several industries, and many more. Trade barriers are further restraining the demand- supply outlook. As government of different regions have already announced total lockdown and temporarily shutdown of industries, the overall production process being adversely affected; thus, hinder the overall Progesterone globally. This report on ‘Progesterone’ provides the analysis on impact on Covid-19 on various business segments and country markets. The report also showcase market trends and forecast, factoring the impact of Covid -19 Situation.

COVID-19 Scenario:

• Due to the global pandemic all over the world, the Progesterone manufacturers are majorly focusing on essential Progesterone production including ventilators and diagnostics.

• However, due to the precautionary measures taken by governments in various regions, the supply chain has been hampered. Which may result in shortage of devices in certain locations.

• Food and Drugs Administration (FDA), on the other hand, shared a COVID-19 guidance with medical device manufacturers to notify the agency about changes that could affect availability of their products.

Progesterone Market Segmentation:

The research offers a detailed segmentation of the global Progesterone market. Key segments analyzed in the research by Device Type, Service Type, End Users and geography. Extensive analysis of sales, revenue, growth rate, and market share of each for the historic period and the forecast period is offered with the help of tables.

Progesterone Market Regional Analysis:

The market is analyzed based on regions and competitive landscape in each region is mentioned. Regions discussed in the study include North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, and Colombia), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa). These insights help to devise strategies and create new opportunities to achieve exceptional results.

Inquiry for Buying @ https://www.alliedmarketresearch.com/purchase-enquiry/3420

Progesterone Market Competitive Analysis:

Estrellas Life Sciences Private Limited, Bionpharma Inc., Sofgen Pharmaceuticals, Teva Pharmaceuticals Industries Ltd., Virtus Pharmaceuticals Llc, Blubell Pharma Group Company, Aquatic Remedies Pvt. Ltd., Intas Pharmaceuticals Ltd., Shanghai Yijing Industrial Co., Ltd., and Wuhan Honor Bio-Pharm Co., Ltd. Provided in this report. These players have adopted various strategies including expansions, mergers & acquisitions, joint ventures, new product launches, and collaborations to gain a strong position in the industry.

Avenue Basic Plan | Library Access | 1 Year Subscription |

Sign up for Avenue subscription to access more than 12,000+ company profiles and 2,000+ niche industry market research reports at $699 per month, per seat. For a year, the client needs to purchase minimum 2 seat plan.

Request for 14 days free trial: https://www.alliedmarketresearch.com/avenue/trial/starter

“We have also published few syndicated market studies in the similar area that might be of your interest. Below are the report title for your reference, considering Impact of Covid-19 Over This Market which will help you to assess aftereffects of pandemic on short-term and long-term growth trends of this market.”

Trending Report Of Healthcare:

Clinical Trial Imaging Market Global Research By 2030

Life Science Analytics Market Global Research By 2030

Diabetes Drugs Market Global Research By 2030

About Us:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned.

David Correa
Allied Analytics LLP
+1 8007925285
Visit us on social media:
Facebook
Twitter
LinkedIn

More Latest News

Media Contacts:


Full Name
Company
Phone Number
Website
Email

Compose your email to at .


  Spam Protection

World’s First Student-Led Global Event on Mental Health & Climate Change

October 9, 2021 (Global News Distribution) -

Students take their future into their own hands by uniting artists, leaders, experts, and activists to discuss The Impact of Climate Change On Mental Health.

In light of the recent IPCC report on the human impacts of climate change, the upcoming G20 climate summit and COP26, the London based organisation World Citizen Artists (WCA) is empowering students to organise a ground-breaking global event in partnership with the World Federation for Mental Health, artists, university associations, and nonprofit organisations.

The two-day online global event is sponsored by World Citizen Artists (WCA), Bristol Students Union, and S&P Global. It will kick off on Saturday November 6th at 2pm on Hopin. The lineup includes panel discussions where students, experts, leaders, activists, and TED speakers will discuss the impact of climate change on people’s psychological well-being.

“Climate change and mental health are global challenges we all face. Empowering the new generation with real-world experience and knowledge means empowering our future. Artists from our community are very supportive of the next generation and it’s been amazing to see students, creatives, leaders, experts and activists getting together to share their common goals. This shows the world can come together no matter what our differences. We should give a chance to the next generation, and help them succeed” – says Valerie Won Lee, founder of WCA.

“At S&P Global, we have witnessed first-hand a growing concern among organisations and investors about the impacts of climate change, with ‘climate anxiety’ presenting a growing threat to mental health”, says Michael Wilkins, Senior Research Fellow, Sustainable Finance at S&P Global Ratings. “To combat this, education is key. This is why we are proud to sponsor this year’s World Citizen Society Global Event, which looks to arm the new generation with the tools and support necessary to cope with change.”

Panelists include Elizabeth Wathuti, Kenyan environmental and climate activist and founder of the Green Generation Initiative. The organisation has planted 30,000 tree seedlings in Kenya. Multi-millionaire tycoon and founder of the World Toilet Organisation, Jack Sim will also be joining one of the panel discussions along with Oxford and Bristol students, as will Claire Gao Pei, climate, sustainability, and energy Representative of the Y20, U.S. delegation to the G20 Youth Summit.

Miss Environment Africa Nazarene University 2021, Fionah Njeri will be joining the interview with international Maori Artist George Nuku.

Musicians, including Colombian artist Marta Gomez, will be performing at the event, using their creative talents to give voice to the challenges humanity is facing.

The event will also offer virtual face to face networking opportunities and discussions on climate change and mental health, and there will be a students’ chill out lounge and an artists’ lounge. The aim is to encourage interaction and constructive debate so that students can learn more about real-world experience from professionals, artists, and activists — and reflect on their role and action when it comes to changing our future.

“As a student at the university of Bristol, I have been volunteering for WCA (on the event) for eight months now. Within this space of time, I’ve learned the leadership skills that I’ve sought elsewhere, but not found. I have willingly been pushed outside of my comfort zone, and have learned the communication skills required in situations I will find myself in for the rest of my working life. I’ve connected with the individuals who have founded the organisations responsible for social change. This has made me realise that all it takes is the courage and motivation to speak up, to create big things. With the skills that I’ve acquired, I now feel empowered with the knowledge that I’m able to fight for social justice” – says Emelye Goult, WCA sponsorship coordinator

Event tickets: https://hopin.com/events/the-impact-of-climate-change-on-mental-health
Early Bird Ticket: Free
Public Ticket: $39
Student Ticket: $5
Artists Ticket: $5
Inclusive Ticket: $5

Tilda Hadley
World Citizen Artists
7840688381 ext.
Visit us on social media:
Facebook
Twitter
LinkedIn

Media Contacts:


Full Name
Company
Phone Number
Website
Email

Compose your email to at .


  Spam Protection

Safety and Efficacy of Topical Epinephrine in Pediatric Dentistry

October 9, 2021 (Global News Distribution) -

Treatment safety and efficacy are extremely important when performing pediatric dental procedures. A new study, published in Anesthesia Progress, found that the use of epinephrine pellets during pediatric zirconia crown placements had positive outcomes in both the safety and efficacy of each treatment.

Anesthesia Progress – The most common chronic disease children experience is dental caries, and routine pediatric dental care is a necessity that assists in oral and whole-body health. However, the majority of children will still require some form of restorative dental care, and that increases in those who do not receive routine dental checkups. Treatment safety and efficacy is imperative when performing pediatric dental procedures.

Researchers from the University of Washington, Seattle; Evidinno Outcomes Research Inc., Vancouver, British Columbia, Canada; and the University of Missouri–Kansas City School of Dentistry, Kansas City, Missouri, recently published a single-blinded, crossover/split-mouth randomized controlled trial in the current issue of Anesthesia Progress that compared cardiovascular safety and hemostatic efficacy of topical epinephrine with a saline placebo.

A total of 13 patients (54% males/46% females), ranging in age from 2.7 to 7.8 years and requiring zirconia crowns on primary maxillary first molars, participated in this study. The researchers measured heart rate (HR), diastolic and systolic blood pressure (D/SBP), and mean arterial pressure (MAP) while the patient was under general anesthesia to monitor cardiovascular function, as well as tracking the time to achieve hemostasis as a measure of clinical efficacy. The patients’ HR, D/SBP, and MAP were recorded immediately before (baseline) epinephrine or saline pellet placement, and then at 1, 2, 3, 4, and 5 minutes after pellet removal.

The researchers found significant decreases in HR, D/SBP, and MAP from baseline to 5 minutes after treatment with epinephrine. In the placebo group, there were significant decreases in HR and SBP, but no significant change in DBP or MAP. During the recording times, there were no clinically significant changes in cardiovascular measurements, and no adverse events in either group. Researchers also note that all 13 teeth in the epinephrine group achieved adequate hemostasis in 2.2 minutes, while only 5 of 13 placebo teeth reached hemostasis within the 5-minute observation window; the remaining 8 teeth required a local anesthetic injection and application of direct pressure to achieve hemostasis.

The results of this study suggest that the use of epinephrine pellets during zirconia crown placement under general anesthesia in children has no negative cardiovascular effects and hemostasis is reached quicker and more effectively. On the findings of this study, lead author Afsoon Fazeli states, “We were reassured by study results but hope there are more clinical studies done so dentists can feel confident in using the epinephrine pellets to improve their efficiency during procedures without concerns about cardiovascular side effects.”

Full text of the article, “Cardiovascular Safety and Hemostatic Efficacy of Topical
Epinephrine in Children Receiving Zirconia Crowns,” Anesthesia Progress, Vol. 68, No. 3, 2021, is available at: https://meridian.allenpress.com/anesthesia-progress/article/68/3/133/471172/Cardiovascular-Safety-and-Hemostatic-Efficacy-of

About Anesthesia Progress

Anesthesia Progress is the official publication of the American Dental Society of Anesthesiology (ADSA). The quarterly journal is dedicated to providing a better understanding of the advances being made in the science of pain and anxiety control in dentistry. The journal invites submissions of review articles, reports on clinical techniques, case reports, and conference summaries. To learn more about the ADSA, visit: http://www.adsahome.org/.

Media Contacts:


Full Name
Company
Phone Number
Website
Email

Compose your email to at .


  Spam Protection

Jaguar Health Provides Updates on Crofelemer and Lechlemer Development Pipeline as well as Merger of Napo EU S.p.A. and Dragon SPAC S.p.A.

October 7, 2021 (Global News Distribution) -

Dragon SPAC and Jaguar subsidiary Napo EU submit required notification to the Italian government in support of consummating the merger

Results accepted for third-party, investigator-initiated Phase 2 HALT-D study evaluating crofelemer for prevention and prophylaxis of diarrhea in breast cancer patients as a poster for December 2021 San Antonio Breast Cancer Symposium

Jaguar Health, Inc. (NASDAQ:JAGX) provided updates today regarding ongoing research and development related to the company’s crofelemer drug product candidates, and also announced that Dragon SPAC S.p.A. and Napo EU S.p.A., the company’s Italian subsidiary, have submitted the required notification in order to have the impending merger of Dragon SPAC and Napo EU approved as required by Italy’s laws.

“We know shareholders and other stakeholders have been looking forward to the consummation of the merger between Dragon SPAC and Napo EU. The requirement for this complex regulatory filing with the Italian government is a new regulation enacted during COVID that applies to transactions regarding pharmaceutical assets in Italy with foreign involvement,” stated Lisa Conte, Jaguar’s president and CEO and Napo EU board member. “We are pleased to have completed submission of this notification and look forward to expanding the Napo EU team in Italy’s Lombardy region – the premier Italian region in the field of life sciences – in support of the goal of developing and commercializing crofelemer throughout Europe for patients in need.”

Napo EU & Dragon SPAC: Short Bowel Syndrome with Intestinal Failure

Napo EU was formed with the mission to expand access to crofelemer to Europe to address important unmet gastrointestinal medical needs in the region. Napo EU’s initial focus is on pursuing the conditional marketing authorization pathway from the European Medicines Agency (EMA) for crofelemer in short bowel syndrome with intestinal failure (SBS-IF), an orphan disease. As announced September 15, 2021, the EMA has confirmed receipt of the Orphan Drug Designation application for crofelemer submitted by Napo EU. Crofelemer has previously received an orphan‑drug designation from the U.S. Food and Drug Administration (FDA) for SBS.

“Following the consummation of the merger of Napo EU and Dragon SPAC, Napo EU will be contributing to the combined entity its exclusive license agreement with Jaguar to the crofelemer/lechlemer pipeline, and Dragon SPAC will contribute financing,” Conte said.

Cancer Therapy-related Diarrhea

The investigators of the Phase 2 cancer therapy-related diarrhea (CTD) study in breast cancer patients (the HALT-D study) have been informed that the poster of the results from the study have been accepted for presentation at the San Antonio Breast Cancer Symposium in December 2021. Specifically, crofelemer effects on diarrhea associated with targeted treatment regimens containing trastuzumab, pertuzumab, docetaxel or paclitaxel and/or carboplatin were evaluated in this study.

As previously announced, the HALT-D study was sponsored by Georgetown University and funded by Genentech, a member of the Roche Group, and is completely independent from the ongoing pivotal Phase 3 clinical trial of crofelemer for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy that was initiated in October 2020 by Jaguar. Enrollment in the crofelemer Phase 3 trial is ongoing. As previously announced, funding for this development program was provided by non-dilutive financing transactions involving the sale of royalty rights related to the company’s future Mytesi® (crofelemer) and lechlemer revenue streams.

Discussion with FDA in September 2021 Regarding Planned Study of NP-300 (Lechlemer) for the Symptomatic Relief of Diarrhea from Acute Infections Such as Cholera

Members of Jaguar’s clinical development team corresponded last month with the US Food and Drug Administration (FDA) as part of a Pre-Investigational New Drug Application (Pre-IND) consultation program. The written correspondence was satisfactory with regard to the company’s plan to file an IND for NP-300 and initiate a Phase 1 trial in the second half of 2022 for the evaluation of NP-300 for the symptomatic relief of diarrhea from acute infections such as cholera, and hence a meeting in September was not necessary.

NP-300 is a standardized and proprietary botanical drug product that is sustainably derived from the Croton lechleri tree. This program is paired with funding from a promissory note related to the potential future sale of a possible tropical disease priority review voucher. Priority review vouchers are granted by the FDA as an incentive to develop treatments for neglected diseases and rare diseases and are transferable.

Canalevia™, Jaguar’s Oral Plant-Based Prescription Drug Candidate for Treatment of Chemotherapy-induced Diarrhea in Dogs

As announced on September 23, 2021, Jaguar has been informed by the FDA’s Center for Veterinary Medicine that the Target Animal Safety technical section of the company’s application for conditional approval of Canalevia for chemotherapy-induced diarrhea (CID) under The Minor Use and Minor Species (MUMS) Animal Health Act has been deemed “Complete”. With the completion of the TAS section – the last of the four major technical sections of Jaguar’s application – Jaguar is planning for the launch of Canalevia for CID in dogs in December 2021.

About Jaguar Health, Inc., Napo Pharmaceuticals, Inc. & Napo EU S.p.A.

Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for GI distress, specifically chronic, debilitating diarrhea. Our wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas. Napo EU S.p.A., the wholly owned Italian subsidiary of Napo Pharmaceuticals, focuses on expanding crofelemer access in Europe and is the named target of Dragon SPAC S.p.A., which closed its financing in July 2021 for gross proceeds of approximately 8,830,000 euros from Jaguar.

For more information about Jaguar, please visit https://jaguar.health. For more information about Napo Pharmaceuticals, visit www.napopharma.com. For more information about Napo EU, visit www.napoeu.com.

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements.” These include statements related to Jaguar’s expectation that Canalevia will launch in December 2021 for CID in dogs. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Contact:
Peter Hodge
Jaguar Health, Inc.
phodge@jaguar.health
Jaguar-JAGX

SOURCE: Jaguar Health, Inc.

Media Contacts:


Full Name
Company
Phone Number
Website
Email

Compose your email to at .


  Spam Protection

MOOD Skin Care Recognized for Their Unique Mental Health-Focused Approach to Skin Care

September 27, 2021 (Global News Distribution) -

MOOD, a European-inspired skin care brand, has been recognized for their unique approach to skin care. By incorporating aromatherapy, MOOD’s products are infused with essential oils that can have mood-enhancing effects. The use of therapeutic-grade essential oils creates a product designed to care for the skin and the mind. All of MOOD’s products contain Broad Spectrum CBD (cannabidiol), which has anti-inflammatory properties. MOOD strictly uses natural, clinic-grade ingredients that were formulated by skin experts and Ayurvedic professionals to create products that are effective in resolving common skin concerns such as acne and hyperpigmentation, while enhancing one’s mental health.

7

“Caring for your skin is an empowering routine, but unfortunately there are a lot of unregulated products on the market that are not as effective as they claim. In fact, some can even be damaging,” said Kristina Centnere, co-founder of MOOD skin care. “At MOOD, we formulate skin care products that create an experience beneficial to both the customer’s skin and their mental state.”

MOOD carries a variety of inclusive products that can be used by all skin types and tones. Their best-selling product of 2021 is a natural skin brightening serum, which contains turmeric, retinaldehyde, kojic acid and licorice root. Unlike many brightening serums on the market that cannot be used by customers with darker skin tones, this product line was specifically designed to be effective and safe for all.

MOOD is committed to mental health beyond its products aromatherapy benefits. A portion of every sale is given to the Anxiety and Depression Association of America to increase awareness about mental health.

MOOD currently offers free shipping for orders in the United States over $50.

For more information, check out their website at www.skincaremood.com.

To follow the latest updates from the company, follow their Instagram at www.instagram.com/itsmoodskincare.

Media Details
Website URL: AscendAgency.com
Company Name: Ascend Agency
Email address: Contact@AscendAgency.com
Country: USA

SOURCE: Mood SkinCare

Media Contacts:


Full Name
Company
Phone Number
Website
Email

Compose your email to at .


  Spam Protection

South Broward (FL) Hospital District Board of Commissioners Adopts Lowest Millage Rate Ever Recorded for the District Despite Challenges Brought on by the Pandemic

September 24, 2021 (Global News Distribution) -

The Board of Commissioners for the South Broward Hospital District, which oversees all actions of the Memorial Healthcare System, voted to adopt the lowest millage rate ever recorded for the district. This latest millage reduction, to 0.1144, marks the 11th year in a row the board lowered the overall millage rate, resulting in the lowest rate in the history of the South Broward Hospital District.

South Florida, like other areas of the country, has experienced serious surges brought on by the COVID-19 pandemic, creating a high demand for healthcare services and challenges across hospitals. Medical teams cared for a high level of COVID-19 cases coupled with steady patient volumes in other clinical areas, such as cardiac and cancer.

Memorial Healthcare System has been on the forefront of the pandemic, managing up to 738 COVID-19 positive patients at the peak of the latest surge, while also investing $16 million in personal protection supplies, and supplementing its front line with close to 1,000 contract nurses to address the constant needs brought on by the pandemic this past year.

Such level of response had significant impact on Memorial’s finances, yet the Board of Commissioners for the South Broward Hospital District, which oversees all actions for Memorial, voted Wednesday to still move forward with the adoption of the lowest millage rate ever recorded for the district. This latest millage reduction to 0.1144 marks the 11th year in a row that the Board has voted to lower the overall millage rate, resulting in the lowest rate in the history of the South Broward Hospital District. Commissioners supported their decision based on Memorial’s strong financial position and having the ability to provide that reduction to residents in south Broward County.

The 0.1144 millage rate represents a 4.59 percent decrease from last year’s rate of 0.1199. The resulting gross tax revenues are estimated to reach $7.7 million. After accounting for early payment discounts and a certain percentage of uncollectible taxes, the anticipated tax payments this year of $7.6 million will provide the District enough revenue to cover its governmental obligations, which include paying Broward County’s Medicaid Match program and community redevelopment agencies in several municipalities in south Broward County, as well as tax collector commissions and property appraiser fees.

The newly adopted millage rate will leave no net tax revenue to fund uncompensated care, the District will use operating income to cover all uncompensated care costs for the entire Memorial Healthcare System, including its six hospitals and its eight Memorial Primary Care clinics. In fiscal year 2022 uncompensated care is projected to exceed $967 million.

On a separate and unanimous vote, the Board of Commissioners also approved an increase in the Memorial minimum wage, from $13 an hour to $15 an hour – an investment of over $8 million in Memorial’s workforce. This is the second minimum wage increase in the last six months.

This historic reduction of this millage rate coupled with the increase in minimum wage also comes at a time when Memorial Healthcare System continues to offer a comprehensive array of services, such as cardiac and stroke care, Level 1 trauma services, maternity, kidney transplant and many others. Memorial’s quality and safety has been recognized nationally by Leapfrog Group, a national nonprofit organization that collects and transparently reports hospital performance. Memorial Cardiac and Vascular Institute continues to receive outstanding ratings from the Society of Thoracic Surgeons, placing Memorial in the top 1% of U.S. cardiovascular centers for 2017. Memorial also remains one of only a handful of public hospitals in the nation to achieve AA, Aa3 financial ratings by Standard and Poor’s and Moody’s, respectively.

Memorial Healthcare System is one of the largest public healthcare systems in the country and is a national leader in quality care and patient satisfaction. Its facilities include Memorial Regional Hospital, Memorial Regional Hospital South, Joe DiMaggio Children’s Hospital, Memorial Hospital West, Memorial Hospital Miramar, Memorial Hospital Pembroke and Memorial Manor nursing home. The system received the following recognitions: Modern Healthcare magazine’s “Best Place to Work in Healthcare,” Florida Trend’s “Florida’s Best Companies to Work For,” and Becker’s Hospital Review’s “150 Great Places to Work in Healthcare.”

For more information, visit mhs.net.

Contact Author

KERTING BALDWIN

Memorial Healthcare System
954-265-1136

Media Contacts:


Full Name
Company
Phone Number
Website
Email

Compose your email to at .


  Spam Protection

ActivePure Medical to Help Protect the 2021 MPCA Annual Conference

September 23, 2021 (Global News Distribution) -

Air and Surface Purification Technology Will Outfit the Michigan Primary Care Association Annual Conference Sept. 26-28

ActivePure Medical, LLC – the healthcare division of ActivePure, the global leader in surface and air purification technology – will provide the Michigan Primary Care Association (MPCA) with products equipped with ActivePure Technology to protect attendees from airborne and surface contaminants at its annual conference this year at the Lansing Center from Sept. 26-28.

ActivePure Medical is sending multiple units with the disinfection technology, including the ActivePure Medical Guardian – an FDA-cleared Class II Medical Device – ActivePure Beyond Guardians and ActivePure Surface & Air Guardians, to protect conference attendees.

ActivePure Technology will help give attendees peace of mind at the event on top of the MPCA’s already rigorous safety guidelines comprised of vaccination requirements, social distancing and mask-wearing. The MPCA’s goal is to host a conference where all attendees have a positive experience reconnecting, networking and sharing ideas in a safe environment, according to the event’s overview.

ActivePure Medical President Dan Marsh and Vice President of Marketing Marissa Ransdell will be in attendance along with ActivePure’s healthcare distributors who will have an exhibit at the show.

“We are honored to have the opportunity to better protect our healthcare heroes attending the conference,” said Marsh. “This event is regularly attended by chief medical officers and CEOs, so it is vital to show our care and concern for their health and safety as they battle to protect those of their patients throughout the COVID-19 pandemic and beyond. ActivePure was designed to tackle the tough pathogens found in the healthcare environment, and we are proud to provide an added layer of protection for the attendees of the conference.”

ActivePure Technology is a proprietary, patented and proven technology that works 24/7 to produce and propel molecules into occupied spaces. The molecules then reduce and inactivate airborne and surface pathogens, including a range of viruses, such as SARS CoV-2 (the virus that causes COVID-19), bacteria, molds and fungi, on contact, by 99.99%.

After the conference concludes, ActivePure Medical will donate the ActivePure units to the MPCA for use at future events.

“Ensuring the highest degree of safety in our learning and professional networking environments is critically important,” said Phillip Bergquist, Chief Operating Officer of the Michigan Primary Care Association. “We are thrilled to have the opportunity to use ActivePure Technology to ensure the well-being of our conference attendees.”

The 2021 MPCA Annual Conference will take place from Sunday, Sept. 26 at 9:30 to Tuesday, Sept. 28 at the Lansing Convention Center, located at 333 E Michigan Ave, Lansing, MI 48933.

###

ABOUT ACTIVEPURE MEDICAL, LLC: 
ActivePure Medical has a 95-year-old parent company, ActivePure, with a deep history in cleaning and disinfecting. Founded under Electrolux USA, ActivePure was established in 1924 and has since operated as a Smithsonian-honored company. In 2020, the ActivePure Medical Guardian received Class II Medical Device clearance from the U.S. Food and Drug Administration (FDA). That same year, the ActivePure Medical division was launched to ensure the company’s healthcare partners have access to a dedicated team of medical infection prevention experts. For more information on ActivePure Medical, please visit ActivePureMedical.com, or call 888-572-6241.

ABOUT MICHIGAN PRIMARY CARE ASSOCIATION (MPCA): 
Michigan Primary Care Association (MPCA) gives a voice to 44 community health centers that provide primary and preventive health care to more than 700,000 patients in rural and urban communities across Michigan. The association advocates to influence and advance health policy in Lansing and Washington, D.C., and offers operational support and training to its health centers to enhance the delivery of integrated care inclusive of primary care, dental, vision and behavioral health. For more information about MPCA, please visit MPCA.net. For more information about the 2021 MPCA Annual Conference, please contact Barb Lincoln at blincoln@mpca.net, or call 517-853-1062.

MEDIA CONTACT: 
Jo Trizila, TrizCom Public Relations on behalf of ActivePure 
Email: Jo@TrizCom.com
Office: 972-247-1369 
Cell/Text: 214-232-0078

SOURCE: ActivePure Medical

Media Contacts:


Full Name
Company
Phone Number
Website
Email

Compose your email to at .


  Spam Protection

Reap the Benefits of Skin-to-Skin Touch with the Nesting Days Carrier for International Babywearing Week

September 9, 2021 (Global News Distribution) -

The lightweight carrier created by a postpartum doula adds comfort and support for moms and infants during the baby’s first months.

Maternal and infant well-being are at the forefront of Nesting Days, designers of innovative babywearing apparel and a brand that is part of a growing movement to recognize the benefits of skin-to-skin touch.

In support of International Babywearing Week on Sept. 27 through Oct. 3, Nesting Days continues to educate the public about the need for comfort and support for postpartum mothers and newborns as they are welcomed into the world.

Created by a postpartum doula, the Nesting Days a lightweight hands-free carrier is a useful tool that helps moms recover from childbirth and C-sections while providing them with the most special skin-to-skin moments with their newborns from day one. The postpartum shaper in the midsection allows moms to heal comfortably while going about with the day’s activities.

“Wrapping newborns is like a second womb for the fourth trimester,” said Nesting Days founder Julie Arvan. “I realized I had the background as a postpartum doula to design a carrier that is in keeping with the latest research on infant development and bonding while offering gentle compression needed for moms as they recover from childbirth.”

By mimicking a womb, the carrier helps soothe the baby when distressed and increases breastfeeding success. Skin-to-skin time is nature’s way for newborns to get the nourishment they need. Wearing a carrier boosts oxytocin levels and lowers cortisol or stress. It also promotes healthy attachment and bonding and aids in learning the baby’s cues for feeding, sleeping and awake time.

Carriers are available for moms and dads, making caregiving a shared experience for lasting memories and bonding time for both parents. The carriers are available in a variety of prints and blend fashion, function, and freedom effortlessly. The patented wing design makes it easier to put on with no buckles, hard edges or straps.

For more information, visit https://www.nestingdays.com.

###

About Nesting Days:
Nesting Days is an innovative, skin-to-skin newborn baby carrier and postpartum body shaper made in San Francisco. Inspired by yoga wear, the Nesting Days carrier is Founder Julie Arvan’s patented design – a safe, wearable ‘nest’ tailored to the unique physiology of the newborn baby combined with a body shaper and skirt that can either be worn down or pulled up over the baby’s bottom for even more support. Although it might look similar to other ‘wraps’ at first glance, its unique winged design and fabric combination provides much more support than possible from any other ‘wrap’ type of carrier available – allowing for hands-free baby carrying for mom (or dad) with no buckles, hard edges or complicated wrapping.

Contact Author

AMBER MASCIORINI

ChicExecs
415-906-4047

Media Contacts:


Full Name
Company
Phone Number
Website
Email

Compose your email to at .


  Spam Protection

Jaguar Health, Inc. Announces 1-for-3 Reverse Stock Split

September 3, 2021 (Global News Distribution) -

  • Reverse split approved by majority of common stock shareholders at December 2020 special meeting of stockholders
  • Shares of Jaguar common stock to begin trading on split-adjusted basis on September 8, 2021

Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”) today announced that the Company will effect a reverse stock split of its issued and outstanding voting common stock (“Common Stock”), at an exchange ratio of 1-for-3, on Wednesday, September 8, 2021 (the “Effective Date”). The Company’s Common Stock will begin trading on a split-adjusted basis when the market opens on the Effective Date and will remain listed on The Nasdaq Capital Market under the symbol “JAGX”. The new CUSIP number for the Company’s Common Stock following the reverse stock split is 47010C607.

The effectuation of the reverse stock split follows the approval of a proposal submitted to Jaguar stockholders at a Special Meeting of Stockholders (the “Special Meeting”). This proposal, which was approved by the affirmative vote of the holders of a majority of the shares of Jaguar Common Stock issued and outstanding as of the record date for the Special Meeting, is described in detail in the Company’s definitive proxy statement on Schedule 14A relating to the Special Meeting filed with the Securities and Exchange Commission (the “SEC”) on November 6, 2020. Stockholders may obtain a free copy of the proxy statement and other documents filed by Jaguar with the SEC at http://www.sec.gov. The proxy statement is also available on the Company’s corporate website.

“We are grateful to our shareholders for voting to approve the proposal for a reverse stock split, and – in support of our strategy of focusing on long-term investors – we have decided to implement a reverse stock split at this time to get Jaguar’s quoted stock price more in line with typical institutional investing requirements,” stated Lisa Conte, Jaguar’s president and CEO.

When the reverse stock split becomes effective, every three (3) shares of the Company’s Common Stock immediately prior to the Effective Date shall automatically be reclassified into one (1) share of Common Stock, without any change in the par value per share, and this change will be reflected on Nasdaq’s website and other stock quote platforms. No fractional shares will be issued as a result of the reverse stock split. Stockholders who otherwise would be entitled to receive a fractional share in connection with the reverse stock split will receive a cash payment in lieu thereof.

American Stock Transfer and Trust Company, LLC is acting as exchange agent for the reverse stock split and will send instructions to stockholders of record who hold stock certificates regarding the exchange of their certificates for post-reverse stock split shares of Common Stock. Stockholders who hold their shares in brokerage accounts or “street name” are not required to take any action to effect the exchange of their shares.

About Jaguar Health, Inc., Napo Pharmaceuticals, Inc. & Napo EU S.p.A.

Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Our wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas. Our Mytesi® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy and the only oral plant-based prescription medicine approved under FDA Botanical Guidance. Napo EU S.p.A., the wholly owned Italian subsidiary of Napo Pharmaceuticals, focuses on expanding crofelemer access in Europe and is the named target of Dragon SPAC S.p.A., which closed its financing in July 2021 for gross proceeds of approximately 8,830,000 euros.

For more information about Jaguar, please visit https://jaguar.health. For more information about Napo Pharmaceuticals, visit www.napopharma.com. For more information about Napo EU, visit www.napoeu.com.

About Mytesi®

Mytesi® (crofelemer delayed release tablets) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi® is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi®. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).

More information and complete Prescribing Information are available at Mytesi.com.

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements.” These include statements regarding Jaguar’s expectation that the Company’s Common Stock will begin trading on a split-adjusted basis when the market opens on the Effective Date. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Contact:
Peter Hodge
Jaguar Health, Inc.
phodge@jaguar.health
Jaguar-JAGX

SOURCE: Jaguar Health, Inc.

Media Contacts:


Full Name
Company
Phone Number
Website
Email

Compose your email to at .


  Spam Protection

Empowers Kai Medical Laboratory Launches Revenue Generating Program Targeting More Than 500 Texas Schools

August 31, 2021 (Global News Distribution) -

U.S. Federal CARES Act Government Funding for COVID-19 Relief in Texas Schools Stands at $17.1B

EMPOWER CLINICS INC. (CSE: CBDT)(Frankfurt:8EC)(OTC PINK: EPWCF) (“Empower” or the “Company“) an integrated healthcare company – serving patients through medical centres, telemedicine platforms and a high complexity medical diagnostics laboratory processing thousands of COVID-19 specimens – is pleased to announce that Empowers Kai Medical Laboratory, LLC (“KAI”) has successfully registered with the U.S. Federal CARES Act Program.

“This designation is a monumental revenue catalyst for KAI,” said Steven McAuley, Chairman and CEO of Empower Clinics. “As the world stands amid another tragic wave of COVID-19, mass vaccinations offer a layer of protection, but widespread testing remains a crucial layer of defence. This heightened demand coupled with generous federal funding puts KAI in the best position to earn significant local revenue. We are kickstarting this designation with a pilot project to offer covered testing in 500 Texas schools. I’m confident this is a strong new catalyst to KAI’s positive work in the testing and research sphere.”

KAI Medical Laboratory is a high complexity laboratory accredited by Clinical Laboratory Improvement Amendments (CLIA) and Commission on Office Laboratory Accreditation (COLA) that offers no-cost coronavirus testing (COVID-19). Under the CARES Act and the Families First Coronavirus Relief Act (FFCRA), patients are generally not responsible for the cost of COVID-19 testing and related services, including co-pays or other out-of-pocket costs. There is no out-of-pocket cost for most uninsured patients through the Federal Health Resources and Services Administration (HRSA) Program for COVID-19 Testing, Treatment, and Vaccine Administration. If HRSA covers a patient’s test, KAI will accept reimbursement from HRSA as payment in full.

Yoshi Tyler, Kai Medical Laboratory President, added, “We are thrilled to be part of this program. And more importantly, we will now expand services to our citizens, neighbours, and community with comprehensive testing that is easy, quick, and provides safe results.”

Through KAI’s certifications and registrations with Medicare, Medicaid, private insurance, and now the Federal CARES Act Program, KAI can provide COVID-19 testing at no charge to patients, thereby covering the total cost for those in need of this essential testing. Kai Medical Laboratory has partnered with On Time Mobile Phlebotomy Services, LLC. to expand its reach for school testing initiatives.

Texas schools have received at least $17.1 billion in federal aid over the course of the pandemic, $13.2 billion of which was allocated as part of the March 2020 CARES Act. The CARES Act opens a trove of opportunities for KAI to deliver accessible testing in both Texas and across the country.

ABOUT THE U.S. CARES ACT
The Coronavirus Aid, Relief, and Economic Security (CARES) Act (2020) is a federal program aimed at providing direct economic assistance related to the COVID-19 pandemic for American workers, families, small businesses, and industries. The Act includes direct economic assistance for Americans among other programs focused on addressing issues related to the COVID-19 pandemic.

This press release is available on the Empower Clinics Verified Forum on AGORACOM for shareholder discussion, questions and engagement with management. https://agoracom.com/ir/EmpowerClinics

ABOUT EMPOWER:
Empower is an integrated healthcare company that provides body and mind wellness for patients through its clinics, with digital and telemedicine care, and world-class medical diagnostics laboratories. Supported by an experienced leadership team, Empower is aggressively growing its clinical and digital presence across North America. Our Health & Wellness and Diagnostics & Technology business units are positioned to positively impact the integrated health of our patients, while simultaneously providing long term value for our shareholders.

ON BEHALF OF THE BOARD OF DIRECTORS:
Steven McAuley
Chief Executive Officer

CONTACTS:
Investors:
Steven McAuley CEO 
s.mcauley@empowerclinics.com
604-789-2146

Investors:
Tamara Mason
Business Development & Communications 
t.mason@empowerclinics.com
416-671-5617

SOURCE: Empower Clinics Inc.

Media Contacts:


Full Name
Company
Phone Number
Website
Email

Compose your email to at .


  Spam Protection